The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1563
ISSUE 1563
January 14, 2019
Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
January 14, 2019 (Issue: 1563)
Tildrakizumab-asmn (Ilumya – Sun), an interleukin
(IL)-23 antagonist, has been approved by the FDA for
treatment of adults with moderate to severe plaque
psoriasis who are candidates for systemic therapy or
phototherapy. Tildrakizumab is the second selective
IL-23 antagonist to be approved for this indication;
guselkumab (Tremfya) was the first.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis
Article code: 1563b
Electronic, downloadable article - $45
Article code: 1563b
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
